Product Description
aTyr 1940 is a recombinant 506 amino acid version of human histidyl-tRNA synthetase (cytoplasmic isoform 1) (HARS; P12081) [1]. HARS belongs to a novel group of naturally occurring proteins termed 'physiocrines' which are extracellular signaling regions of tRNA synthetases reported to modulate immune system pathways. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=8738)
Mechanisms of Action: RNA Synthetase Analogue
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: aTyr Pharma
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophies, Limb-Girdle
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12619000770167p |
RNN/246/20/KE | N/A |
Not yet recruiting |
Osteoarthritis|Carpal Tunnel Syndrome |
2029-06-15 |
|||
NCT02836418 |
FSHD | P2 |
Completed |
Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophies, Limb-Girdle |
2017-04-18 |
2023-12-23 |
Primary Endpoints |
|
2016-000624-25 |
2016-000624-25 | P2 |
Terminated |
Muscular Dystrophies, Limb-Girdle|Muscular Dystrophy, Facioscapulohumeral |
2017-04-18 |
2022-03-13 |
Treatments |
|
2014-001753-17 |
2014-001753-17 | P2 |
Completed |
Muscular Dystrophy, Facioscapulohumeral |
2017-01-04 |
2025-06-25 |
Treatments |
|
NCT02603562 |
FSHD | P2 |
Completed |
Muscular Dystrophy, Facioscapulohumeral |
2016-12-12 |
2023-10-20 |
Primary Endpoints |
|
2015-001910-88 |
2015-001910-88 | P2 |
Completed |
Muscular Dystrophies, Limb-Girdle|Muscular Dystrophy, Facioscapulohumeral |
2016-10-05 |
2022-03-13 |
Treatments |
|
NCT02579239 |
FSHD | P2 |
Completed |
Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophies, Limb-Girdle |
2016-10-05 |
2023-10-20 |
||
2015-001912-36 |
2015-001912-36 | P2 |
Terminated |
Muscular Dystrophy, Facioscapulohumeral |
2016-08-04 |
2022-03-13 |
Treatments |
|
NCT02531217 |
ATYR1940-C-005 | P2 |
Completed |
Muscular Dystrophy, Facioscapulohumeral |
2016-05-26 |
2023-08-19 |
Primary Completion Date|Primary Endpoints|Start Date |
|
NCT02239224 |
ATYR1940-C-002 | P2 |
Completed |
Muscular Dystrophy, Facioscapulohumeral |
2015-12-14 |
2021-08-12 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
2014-003346-27 |
2014-003346-27 | P2 |
Terminated |
Muscular Dystrophy, Facioscapulohumeral |
None |
2022-03-13 |
Treatments |